Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine

Abstract

Neurodegenerative diseases (NDDs) are characterized by selective dysfunction and loss of neurons associated with pathologically altered proteins that deposit in the human brain but also in peripheral organs. These proteins and their biochemical modifications can be potentially targeted for therapy or used as biomarkers. Despite a plethora of modifications demonstrated for different neurodegeneration-related proteins, such as amyloid-β, prion protein, tau, α-synuclein, TAR DNA-binding protein 43 (TDP-43), or fused in sarcoma protein (FUS), molecular classification of NDDs relies on detailed morphological evaluation of protein deposits, their distribution in the brain, and their correlation to clinical symptoms together with specific genetic alterations. A further facet of the neuropathology-based classification is the fact that many protein deposits show a hierarchical involvement of brain regions. This has been shown for Alzheimer and Parkinson disease and some forms of tauopathies and TDP-43 proteinopathies. The present paper aims to summarize current molecular classification of NDDs, focusing on the most relevant biochemical and morphological aspects. Since the combination of proteinopathies is frequent, definition of novel clusters of patients with NDDs needs to be considered in the era of precision medicine. Optimally, neuropathological categorizing of NDDs should be translated into in vivo detectable biomarkers to support better prediction of prognosis and stratification of patients for therapy trials.

Paving the Way Toward Complex Blood-Brain Barrier Models Using Pluripotent Stem Cells

“…Also, other neurological syndromes are highly cell-type specific, such as AD, PD, and HD. Selective loss of neurons in these diseases leads to impaired cognitive and mobile function, depending on the site and severity of neural loss [82]. Not long after iPSCs were first produced came the first publication of iPSCs generated from patients with neurofibromatosis type 1 disease [83].…”

Can Creutzfeldt-Jakob disease unravel the mysteries of Alzheimer?

“…Like PrP, most of the neurodegenerative conditions are characterized also by the deposition of physicochemically modified disease-related proteins, such as amyloid-β (Aβ), α-synuclein, tau or TAR-DNA-binding protein 43 kDa (TDP-43) 2 . The concept of protein-based classification of neurodegenerative diseases is widely accepted 2 .…”

“…Like PrP, most of the neurodegenerative conditions are characterized also by the deposition of physicochemically modified disease-related proteins, such as amyloid-β (Aβ), α-synuclein, tau or TAR-DNA-binding protein 43 kDa (TDP-43) 2 . The concept of protein-based classification of neurodegenerative diseases is widely accepted 2 . It seems that misfolding of endogenous proteins can lead to proteinaceous seeds, which can serve as self-propagating agents associated with the progression of the specific disease 3 .…”

Precision Medicine - The Golden Gate for Detection, Treatment and Prevention of Alzheimer’s Disease

“…Despite the huge potential of advanced systems-level approaches applied to multifactorial diseases, the reality is that evolving precision medicine initiatives for AD and other neurodegenerative diseases (1, 20–22, 41) are still missing the essential SB framework, which is key for the successful implementation and operationalization of precision medicine strategies (Figure 1). This critical issue needs to be fully corrected in order to advance healthcare towards “true precision medicine”.…”